Molluscum Treatment Cleared Skin Four Times Faster
A new pooled analysis of clinical trials shows how this topical therapy impacts skin clearance rates for patients.
Updated on Oct. 5, 2026 in Diseases — General
Live Poll
Do you prefer to treat minor skin infections immediately rather than waiting for them to resolve?
Patients treated with the topical therapy YCANTH achieved complete clearance of molluscum contagiosum four times faster than those in a vehicle control group. These findings were identified through a post-hoc analysis of pooled data from two Phase 3 clinical trials.
Why it matters
This analysis provides new clarity on the efficacy of VP-102, confirming that the treatment's effect persists regardless of how long a patient has had the infection. Understanding these comparative clearance rates helps patients and their physicians evaluate treatment expectations.
A post-hoc analysis of the completed CAMP-1 and CAMP-2 Phase 3 trials reported a hazard ratio of 4.06 for complete lesion clearance. By Day 84, 60.1% of patients using VP-102 achieved total clearance compared to 19.9% of the vehicle group.
The players
Verrica Pharmaceuticals
A medical dermatology company headquartered in West Chester, PA, focused on developing treatments for skin diseases like molluscum contagiosum.
The details
The analysis compared results from patients receiving the topical therapy VP-102 against those receiving a vehicle treatment. By pooling the data, researchers were able to calculate a hazard ratio of 4.06, with sensitivity estimates ranging from 4.05 to 4.19, illustrating a significant increase in the rate of lesion resolution. This effect remained consistent across the study population, irrespective of the prior duration of the molluscum contagiosum infection.
Timeline
Day 84 marked the point where cumulative complete clearance reached 60.1% for VP-102.
October 8-11, 2026, is when the Fall Clinical Dermatology Conference takes place in Las Vegas.
October 15-17, 2026, is the schedule for the Pediatric Dermatology Research Alliance Annual Conference.
Health Landscape
This analysis provides a more granular look at the data initially generated by the CAMP-1 and CAMP-2 Phase 3 clinical trials. It follows a standard pattern in clinical research where pooled analysis is used to refine the understanding of treatment efficacy across broader cohorts.
If you are managing molluscum contagiosum, these findings help establish clearer expectations for how quickly skin might clear with professional treatment. Discuss these clearance rates and whether this therapy is an appropriate option for your specific case with your dermatologist.
The takeaway
This data reinforces that consistent treatment can lead to faster resolution of molluscum lesions compared to no active therapy. If you are experiencing symptoms, consult your physician to track your progress and discuss the most effective intervention path for your skin health.
What happens next
Verrica Pharmaceuticals will present these findings at the Fall Clinical Dermatology Conference in Las Vegas from October 8-11, 2026, and at the Pediatric Dermatology Research Alliance Annual Conference from October 15-17, 2026.
Further reading
For more information on skin condition management, visit Diseases — General.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you prefer to treat minor skin infections immediately rather than waiting for them to resolve?
